ALMR · Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY and…

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY and above the $30.2M consensus, with EPS of -$0.19 in line with the -$0.19 estimate. The company raised full-year 2026 revenue guidance to $121M-$123M from $116M-$120M, reflecting 64% midpoint growth. President Tod White announced retirement at year-end, a neutral leadership transition.

• Q3 2026 total revenue $33.5M, up 68% from $19.9M YoY, above $30.2M consensus
• Consumable revenue grew 79% to $17.8M; instrument revenue grew 50% to $8.5M
• Gross margin improved to 61.5% from 59.7% YoY
• Net loss $13.3M vs $8.0M YoY; EPS -$0.19 in line with consensus